Prognostic value of circulating tumor DNA in operable non-small cell lung cancer: a systematic review and reconstructed individual patient-data based meta-analysis

[1] Siegel RL(2023)Cancer statistics, 2023 CA Cancer J Clin 73 17-48

[2] Miller KD(2016)Cancer statistics in China, 2015 CA Cancer J Clin 66 115-132

[3] Wagle NS(2022)Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial Lancet 399 1607-1617

[4] Chen W(2022)Using circulating tumor DNA in colorectal cancer: current and evolving practices J Clin Oncol 40 2846-2857

[5] Zheng R(2021)ctDNA guiding adjuvant immunotherapy in urothelial carcinoma Nature 595 432-437

[6] Baade PD(2022)Circulating tumor DNA minimal residual disease detection of non-small-cell lung cancer treated with curative intent J Clin Oncol 40 567-575

[7] Saji H(2022)Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer Nat Med 28 2353-2363

[8] Okada M(2018)Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection Nat Rev Clin Oncol 15 577-586

[9] Tsuboi M(2017)Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution Nature 545 446-451

[10] Malla M(2022)Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients Transl Lung Cancer Res 11 263-276

[1] Siegel RL(2023)Cancer statistics, 2023 CA Cancer J Clin 73 17-48

[2] Miller KD(2016)Cancer statistics in China, 2015 CA Cancer J Clin 66 115-132

[3] Wagle NS(2022)Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial Lancet 399 1607-1617

[4] Chen W(2022)Using circulating tumor DNA in colorectal cancer: current and evolving practices J Clin Oncol 40 2846-2857

[5] Zheng R(2021)ctDNA guiding adjuvant immunotherapy in urothelial carcinoma Nature 595 432-437

[6] Baade PD(2022)Circulating tumor DNA minimal residual disease detection of non-small-cell lung cancer treated with curative intent J Clin Oncol 40 567-575

[7] Saji H(2022)Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer Nat Med 28 2353-2363

[8] Okada M(2018)Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection Nat Rev Clin Oncol 15 577-586

[9] Tsuboi M(2017)Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution Nature 545 446-451

[10] Malla M(2022)Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients Transl Lung Cancer Res 11 263-276